ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bracco and Jiangsu HengRui Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BraccoJiangsu HengRui Medicine
studies on the registry661,066
open to participants now5307
phase 3 studies under way1105
reach primary completion within a year0130
programswith a study of their own in two years3155+1 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBraccoJiangsu HengRui Medicine
Phase 100%

Jiangsu HengRui Medicine: 52 of its 155 programs at phase 1

  1. Rifampinphase 1
  2. HRS-5817phase 1
  3. HRS-2189phase 1
  4. SHR-2017phase 1
  5. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

and 47 more — sign in to see them all

34%
Phase 2

Bracco: 2 of its 3 programs at phase 2

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2
67%

Jiangsu HengRui Medicine: 50 of its 155 programs at phase 2

  1. SHR-1139phase 2
  2. SHR-1826phase 2
  3. SHR-9839phase 2
  4. SHR-2173phase 2
  5. HRS-4508phase 2

and 45 more — sign in to see them all

32%
Phase 300%

Jiangsu HengRui Medicine: 51 of its 155 programs at phase 3

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  4. ribupatidephase 3
  5. notiretatug rezetecanphase 3

and 46 more — sign in to see them all

33%
Approved, new studies

Bracco: 1 of its 3 programs at approved, new studies

  1. fluciclovine F-18approved, new study
33%

Jiangsu HengRui Medicine: 2 of its 155 programs at approved, new studies

  1. vunakizumabapproved, new study
  2. remimazolam tosylateapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bracco0 readouts · 0 phase 3············
Jiangsu HengRui Medicine76 readouts · 11 phase 3

Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion

  1. HRS-1780phase 3 · Nov 0 · NCT07470983
  2. SHR-1681phase 2 · Nov 0 · NCT06737731

Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3

  1. adebrelimabphase 3 · Dec 0 · NCT05482568
  2. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1 · Dec 0 · NCT06443489
  3. BP102phase 3 · Dec 0 · NCT06915142
  4. drotokibartphase 3 · Dec 0 · NCT07688772
  5. HRS-1596phase 1 · Dec 0 · NCT07841860

and 27 more — sign in to see them all

Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. RSS0393phase 3 · Jan 0 · NCT07543224
  2. SHR 3201phase 1 · Jan 0 · NCT07889349
  3. SHR-4375phase 2 · Jan 0 · NCT07298772
  4. HRS-5817phase 1 · Jan 30 · NCT07238647

Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion

  1. FH-006phase 3 · Feb 0 · NCT07136142
  2. HRS-5346phase 2 · Feb 0 · NCT07767513
  3. HRS-8080phase 3 · Feb 0 · NCT07876596
  4. KRAS G12D Inhibitor HRS-4642phase 3 · Feb 0 · NCT07906691
  5. RSS0343phase 2 · Feb 0 · NCT07940829

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3 · Mar 0 · NCT06929624
  2. HRS-1893phase 3 · Mar 0 · NCT07269717
  3. HRS-4139phase 1 · Mar 0 · NCT07802964
  4. HRS-4729phase 2 · Mar 0 · NCT07690826
  5. ivarmacitinibphase 3 · Mar 0 · NCT07251595

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion

  1. HRS-4029phase 2 · Apr 0 · NCT07739160
  2. HRS-5632phase 2 · Apr 0 · NCT07185776
  3. SHR-1703phase 3 · Apr 0 · NCT07701239
  4. SHR-2173phase 2 · Apr 0 · NCT07354932
  5. SHR-4602phase 2 · Apr 0 · NCT06704828

and 1 more — sign in to see them all

Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion

  1. SHR-4712phase 1 · May 0 · NCT06993116

Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-7249phase 2 · Jun 0 · NCT07308392
  2. HRS8179phase 3 · Jun 0 · NCT06732648
  3. SHR-1819phase 3 · Jun 0 · NCT07321951
  4. SHR-1918phase 3 · Jun 0 · NCT07308392
  5. SHR-9803phase 2 · Jun 0 · NCT06906731

Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Jul 0 · NCT07682272
  2. ruzinuradphase 3 · Jul 0 · NCT07362355
  3. aumolertinibphase 3 · Jul 30 · NCT05503888
  4. retlirafusp alfaphase 3 · Jul 30 · NCT05503888
  5. SHR-9539phase 1 · Jul 31 · NCT06484777
·

Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-4508phase 2 · Sep 0 · NCT07003321
  2. garetatug rezetecanphase 3 · Sep 20 · NCT06649292

Jiangsu HengRui Medicine, Oct ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-5965phase 3 · Oct 0 · NCT07014826
  2. SHR-2524phase 1 · Oct 0 · NCT07478302
  3. Trastuzumabphase 3 · Oct 0 · NCT07140393
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bracco

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Jiangsu HengRui Medicine

New programs 11

Reached a new phase 4

  • SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
  • HRS-6209phase 3 · Oct 14 · Breast Neoplasms
  • HRS-7172phase 2 · Sep 2 · Lung Neoplasms
  • FH-006phase 3 · Aug 25 · Lung Neoplasms

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionBraccoJiangsu HengRui Medicine
Prostatic Neoplasmsboth · compare here

Bracco in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 2
  2. fluciclovine F-18approved, new study

Their studies: Bracco’s studies of Prostatic Neoplasms in search

Jiangsu HengRui Medicine in Prostatic Neoplasms: 11 programs

  1. zeprumetostatphase 3
  2. rezvilutamidephase 3
  3. HRS-4357phase 3
  4. GnRH Antagonist SHR7280phase 3
  5. HRS-5041phase 2

and 6 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

Bracco in Breast Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Breast Neoplasms in search

Jiangsu HengRui Medicine in Breast Neoplasms: 9 programs

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. HRS-8080phase 3
  4. ruzaltatug rezetecanphase 3
  5. HRS-6209phase 3

and 4 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bracco in Colorectal Neoplasms: 2 programs

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2

Their studies: Bracco’s studies of Colorectal Neoplasms in search

Jiangsu HengRui Medicine in Colorectal Neoplasms: 4 programs

  1. trastuzumab rezetecanphase 3
  2. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  3. BP102phase 3
  4. Trastuzumabphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Colorectal Neoplasms in search

Carcinoma, Renal Cellboth · compare here

Bracco in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Carcinoma, Renal Cell in search

Jiangsu HengRui Medicine in Carcinoma, Renal Cell: 2 programs

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  2. SHR-4610phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Carcinoma, Renal Cell in search

Urinary Bladder Neoplasmsboth · compare here

Bracco in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Urinary Bladder Neoplasms in search

Jiangsu HengRui Medicine in Urinary Bladder Neoplasms: 1 program

  1. notiretatug rezetecanphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Urinary Bladder Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bracco 2 of 3 · Jiangsu HengRui Medicine 67 of 155 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Jiangsu HengRui Medicine: 1).